were made to better apply this screen in high altitude wilderness settings. We removed 5 the clock drawing task given the practical concern of needing to remove gloves to 6 perform the test in a very cold environment. The clock drawing test is useful to assess 7 visuospatial cognition, but is clinically a less useful subtest when compared to other 8 elements in the Qmci (O'Caoimh et al., 2013). Instead, in order to maintain a distracting 9 task before the verbal recall exam, subjects were asked to count backwards from 100 by 10 sevens. A second modification was made in which proper names replaced common 11 names for repetition and recall testing. Proper names were matched for frequency of 12 occurrence in the English language. High altitude seems to have a more dramatic effect 13 on the recall of proper names while recall of common names is relatively resistant to 14 hypoxia (Pelamatti et al., 2003) . The remaining subtests were unchanged. Subjects with 15 normal cognition have a median score of 75 (O'Caoimh R, 2014). Subjects who score ≤ 16 67 out of 100 meet criteria for mild CI and those who score ≤ 53 out of 100 meet criteria 17 for dementia (O'Caoimh R, 2014). 18 
19

Statistical Analysis 20
Continuous variables were compared using two-sample t-tests while categorical variables 21
were measured using frequency and percentage and compared using chi-square tests. The 22 relationship between the two measures was summarized using a Spearman correlation 23 coefficient. Two-sided p values ≤ 0.05 were considered as statistically significant. All 1 analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). 2 3
Results
4
Seventy-nine subjects were enrolled in the study. All subjects who enrolled completed 5 the surveys. Twenty-two subjects (28 %) met criteria for AMS and 17 subjects (22 %) 6 met criteria for mild CI. 7 8   Table I presents demographic subject information stratified by presence of AMS and CI. 9
We found a significant difference in recent acetazolamide use between groups with and 10 without AMS. Twenty-three out of 79 (29 %) took acetazolamide in the last 24 hours. Of 11 these subjects, 10 (43 %) had AMS and 11 (48 %) had CI. A higher percentage of 12 subjects diagnosed with AMS had taken acetazolamide in the previous 24 hours 13 compared to those without AMS (45 % vs. 23 %, p = 0.047). Similarly, a higher 14 percentage of subjects with CI had taken acetazolamide in the last 24 hours compared to 15 those without CI (65 % vs. 19 %, p = 0.0003). Subjects with CI were slightly older (37 ± 16 14 vs. 29 ± 9, p = 0.058) and there were no other significant differences in group 17 characteristics [e.g. age, sex, nationality, education, days above 8000 ft, self-rated 18 experience at high altitude, and paracetamol and non-steroidal anti-inflammatory 19 (NSAID) use] in subjects with and without AMS, or with and without CI. 20 
21
As this study tested subjects at two different altitudes, we also analyzed the results from 22
only Manang, where the majority of subjects were recruited (n = 62). When subjects from 23 Thorong Phedi were excluded, there was still a significant difference in recent 1 acetazolamide use between groups with and without AMS. Specifically, a higher 2 percentage of subjects diagnosed with AMS had taken acetazolamide in the last 24 hours 3 compared to those without AMS (44 % vs. 13 %, p = 0.009). Similarly, a higher 4 percentage of subjects with CI had taken acetazolamide in the last 24 hours compared to 5 those without CI (54 % vs. 12 %, p = 0.001). There were no other significant differences 6 in group characteristics. 7
8
There was a very weak correlation between the eQmci score and LLS based on the 9
Spearman correlation coefficient (r = -0.24, p = 0.04) as only 5% of the variance in the 10 eQmci can be attributed to LLS (see Figure 1 ). Among the 79 subjects, 6 (8 %) tested 11 positive for both AMS and CI and 46 (58 %) tested negative for both. Sixteen subjects 12 (20 %) met the LLS criteria for AMS but had no CI. The remaining 11 subjects (14 %) 13 were cognitively impaired but did not have AMS. Those with concordance between the 14 eQmci and LLS were more likely to be male (69 % vs. 41 %, p = 0.014) and there was no 15 other significant difference in subject demographic characteristics between those with 16 and without concordance between the eQmci and LLS. 17 
18
Components of the LLS were also analyzed as presented in Table II . There was no strong 19 correlation between the eQmci score and any of the LLS components, including 20 headache. The strongest correlation was seen in gastrointestinal symptoms, which was 21 still relatively weak (r = -0.28, p = 0.011). 22 We conducted a further analysis to examine the effect of acetazolamide on eQmci score. 1 Figure 2 shows the distribution of eQmci from those subjects with and without 2 acetazolamide use in the last 24 hours. The overall mean eQmci scores were lower in 3 subjects who took acetazolamide (69 vs. 77, p = 0.0007). The finding was consistent 4 when limited to subjects with the same LLS score. Table III compares the prevalence of  5 CI from subjects with and without acetazolamide use in the last 24 hours. Overall, CI 6 were more common among subjects with acetazolamide use (47.8% vs. 10.7 %, p = 7 0.0006). When stratified by AMS status, the finding remained consistent. Among those 8 without AMS, CI was significantly more frequent in subjects who took acetazolamide 9 than in subjects who had not taken the drug (46.2 % vs. 11.4 %, p = 0.011). Similarly, 10 among subjects with AMS, those who took acetazolamide showed a trend to have more 11 CI (50.0 % vs. 8.3 %, p = 0.056) than those who had not taken the drug. Denali. While they demonstrated deficits in learning and retention in perceptual and 5 memory tasks, they did not correlate with AMS. In one study that tested mental capacity, 6 subjects with AMS were worse in pursuit aiming compared to subjects without AMS, but 7 in the remaining battery of cognitive tests, no significant differences were found (Bian et 8 al., 2015) . It is possible that there is a difference in the aspects of cognitive deficits seen 9 with and without AMS. In the study by Regard et al. (1991) , subjects simulated ascent to 10 4500 m (14,734 ft) over 24 hours in a hypobaric chamber. Those with AMS had 11 deficiencies in short-term memory, but improved in conceptual tasks while those without 12 AMS had improved short-term memory, but no improvement in conceptual tasks (Regard 13 et al., 1991) . 14 
15
The lack of any relationship in our study and in others between CI and AMS, both of Our study found a surprisingly high prevalence of CI: 17 subjects (22 %) met criteria for 5 mild CI. In subjects with an age range similar to that in our study, no subject tested at 6 sea-level was found to have CI (Molloy, 2015 ). An incidental finding of our study was 7 that acetazolamide use, independent of the severity of AMS was associated with CI at 8 high altitude. 9
10
The discriminating power of the Qmci for detecting CI is influenced by age; specifically 11 it is less accurate for subjects older than 75 years (O'Caoimh, 2014). The cut-off of 67 12 used in this study is recommended for younger adults (≤ 75 years) with more education 13 (≥ high school). All subjects in our study were in this category. At this cut-off the Qmci 14 has 86 % sensitivity and 89 % specificity for detecting the presence of mild CI. CI is not 15 seen in a young healthy educated population (Molloy, 2015) . Sex does not significantly 16 affect cut-off scores (O'Caoimh R, 2014). 17 
18
Acetazolamide and cognitive impairment 19
In subjects taking acetazolamide, we found a high incidence of both AMS and of CI. 20
Acetazolamide has been associated with confusion (Swenson, 2014) . In a randomized 21 study of subjects at high altitude, subjects who received prophylactic acetazolamide (125 22 mg twice per day) had impaired neuropsychological measures of concentration, cognitive 23 processing speed, reaction time, short-term memory, and working memory (Wang et al., 1 2013). In a similar study, subjects who took acetazolamide (500 mg slow release, once 2 per day) actually showed improvement in certain psychological tests (White, 1984) . In 3 addition to higher daily acetazolamide dosing, this second study differed from the former 4 in that subjects traveled on foot rather than being airlifted to a higher altitude which may 5 be a confounding factor. A more recent study found that at sea level, acetazolamide use is 6 associated in a dose-dependent fashion with a spectrum of psychometric impairments, 7 including poor concentration, imbalance and slower reaction time responses (Collier, 8 2016) . Our study did not differentiate between prophylactic or treatment doses, but a 9 future study can be designed to match groups with regard to this variable. with concurrent bicarbonate supplementation sufficient to correct the metabolic acidosis 19 (Lichter, 1981) . 20 
21
Limitations of the study
There are several limitations in this investigation. First, we made modifications to the 1 eQmci (the clock drawing task was replaced by reciting serial sevens and the repetition 2 and recall of names were changed from common to proper). Though Second, traveling to a distant, culturally unfamiliar location may alter one's performance 7 on a cognitive test. Third, there was a relatively small sample size. Other trends may be 8 been seen with a more robust sample. Unfortunately, our recruitment was limited as a 9 result of the devastating 2015 earthquake in Nepal, which resulted in premature 10 termination. Fourth, there may be several secondary influences on neuropsychological 11 function including fatigue, hypothermia, desynchronosis, upper respiratory infections, 12 and exposure to a new environment. An individual diagnosis was not recorded for every 13 patient. However, most presentations to the clinic that were unrelated to altitude were 14 quite minor (e.g. blisters) and would not be expected to affect cognitive function. Fifth, 15 there was no low-altitude control group, nor were our subjects tested at low altitude to 16 examine baseline scores. Sixth, there were no measurements of arterial oxygenation 17 saturation by pulse oximetry. In future studies, this would be a better indicator of cerebral 18 hypoxic stress than the actual altitude. Seventh, there were no longitudinal data to 19 determine if low eQmci scores correlate with the development of HACE. Defining the 20 clinical significance of mild CI and determining whether it can it be used to predict those 21 that will develop HACE or experience other clinical relevant sequelae are areas of future 22
research. In addition, there were no longitudinal data on the discontinuation of 23 acetazolamide. Eighth, subjects were studied at two different altitudes. However, the 1 results were not significantly changed when the data were limited to Manang, where most 2 subjects were tested. Ninth, in a convenience sample, in which subject self-selection 3 exists (researchers have no control or insight in subjects' decisions to continue to ascend 4 or not), unmeasured confounding variables may exist that could reduce the validity of our 5 conclusions. In summary, our data demonstrate only a weak correlation between the LLS and eQmci, 5 but a surprising prevalence of CI, an objective measure of CNS dysfunction, at high 6 altitude. CI was prevalent in subjects both with and without AMS. The presence of CI in 7 otherwise asymptomatic trekkers raises concerns for unrecognized CI at altitude. 8
Furthermore, we found that acetazolamide use, independent of the severity of AMS was 9 associated with CI at high altitude. Further research using CI testing may help define 10 objective measures of CNS dysfunction at altitude. The overall mean eQmci scores were significantly lower in subjects that took 5 acetazolamide. 
